We examined the effects of temperature and inoculum on the agreement of macro-and microdilution broth Drugs. SCH 39304 (Schering-Plough Research Corp., Bloomfield, N.J.), fluconazole (Pfizer Research, Groton, Conn.), amphotericin B (E. R. Squibb & Sons, Princeton, N.J.), and ketoconazole (Janssen Pharmaceutical, Inc., Piscataway, N.J.) were used to prepare 1-mg/ml stock solutions in 2% dimethyl sulfoxide (Sigma Chemical Co., St. Louis, Mo.) for the triazoles and 10% dimethyl sulfoxide for the other drugs. Stock solutions of flucytosine (Hoffmann-La Roche Inc., Nutley, N.J.) were prepared at a concentration of 10 mg/ml in 10% dimethyl sulfoxide. All drugs were stored at -700C.Media and buffers. Unbuffered synthetic amino acid media for fungi (SAAMF) were prepared as previously described (2, 6), except that solutions of amino acids (Irvine Scientific Sales Co., Inc., Santa Ana, Calif.) were used instead of powdered amino acids and cystine was replaced with equimolar amounts of cysteine (7). Yeast nitrogen broth (Difco), RPMI 1640 (Sigma), and high-resolution broth (kindly supplied by Peter Troke, Pfizer Inc., Sandwich, England) were prepared as specified by the manufacturers, sterilized by filtration, and stored at 4°C. On the day of use, morpholinepropanesulfonic acid (MOPS) buffer (Sigma) was added to each medium to a final concentration of 0. 165 M, the pH was adjusted to 7.0 with 10 M sodium hydroxide or 6 M hydrochloric acid, and the medium was resterilized by filtration.Susceptibility testing. Macrodilution broth assays were performed as previously described (8,9). Briefly, twofold dilutions of the antifungal agents were prepared by standard methods (10) in media to 10 times the final concentrations, as listed below. Yeast inocula were prepared by suspending 1542